Company profile PYXS

Pyxis Oncology Inc
pyxis oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.
Quarter analysis & expected interestLast update: February 09 2024 03:47:46.

After 39 days of this quarter the interest is at 8.0. Based on that we can calculate that during remaining 52 days it will total up to 19.0.
Pyxis Oncology expected interest is significantly lower compared to same quarter last year (-85.5%) but higher than previous quarter (+46.2%).

YearQ1Q2Q3Q4
20190
1
inf% QoQ
5
400.0% QoQ
4
-20.0% QoQ
2020 3
inf% YoY -25.0% QoQ
2
100.0% YoY -33.3% QoQ
2
-60.0% YoY 0.0% QoQ
2
-50.0% YoY 0.0% QoQ
2021 6
100.0% YoY 200.0% QoQ
5
150.0% YoY -16.7% QoQ
10
400.0% YoY 100.0% QoQ
13
550.0% YoY 30.0% QoQ
2022 11
83.3% YoY -15.4% QoQ
7
40.0% YoY -36.4% QoQ
6
-40.0% YoY -14.3% QoQ
7
-46.2% YoY 16.7% QoQ
2023 131
1090.9% YoY 1771.4% QoQ
73
942.9% YoY -44.3% QoQ
18
200.0% YoY -75.3% QoQ
13
85.7% YoY -27.8% QoQ
2024 8
-93.9% YoY -38.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Pyxis Oncology search interestLast update: February 09 2024 03:47:46.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 03:47:48.

The average 5 years interest of Pyxis Oncology was 1.25 per week.
The last year interest of Pyxis Oncology compared to the last 5 years has changed by 269.6%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 2331.58%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 03:47:58.

After 39 days of this quarter the interest is at 9.0. Based on that we can calculate that during remaining 52 days it will total up to 21.0.
Pyxis Oncology stock expected interest is significantly lower compared to same quarter last year (-83.2%) but higher than previous quarter (+75.0%).

YearQ1Q2Q3Q4
20190
0
7
inf% QoQ
9
28.6% QoQ
2020 2
inf% YoY -77.8% QoQ
6
inf% YoY 200.0% QoQ
6
-14.3% YoY 0.0% QoQ
4
-55.6% YoY -33.3% QoQ
2021 7
250.0% YoY 75.0% QoQ
5
-16.7% YoY -28.6% QoQ
0
-100.0% YoY -100.0% QoQ
7
75.0% YoY inf% QoQ
2022 2
-71.4% YoY -71.4% QoQ
6
20.0% YoY 200.0% QoQ
4
inf% YoY -33.3% QoQ
2
-71.4% YoY -50.0% QoQ
2023 125
6150.0% YoY 6150.0% QoQ
77
1183.3% YoY -38.4% QoQ
16
300.0% YoY -79.2% QoQ
12
500.0% YoY -25.0% QoQ
2024 9
-92.8% YoY -25.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Pyxis Oncology stock search interestLast update: February 09 2024 03:47:57.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 03:48:00.

The average 5 years interest of Pyxis Oncology stock was 1.17 per week.
The last year interest of Pyxis Oncology stock compared to the last 5 years has changed by 288.03%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 1364.52%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pyxis Oncology clinical trials to provide analysis

Correlation between past revenue and Pyxis Oncology clinical trials search interest

There is not enough data for Pyxis Oncology clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pyxis Oncology clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pyxis Oncology antibody therapies to provide analysis

Correlation between past revenue and Pyxis Oncology antibody therapies search interest

There is not enough data for Pyxis Oncology antibody therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pyxis Oncology antibody therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pyxis Oncology cancer treatments to provide analysis

Correlation between past revenue and Pyxis Oncology cancer treatments search interest

There is not enough data for Pyxis Oncology cancer treatments to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pyxis Oncology cancer treatments to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pyx-106 Phase 1 trial to provide analysis

Correlation between past revenue and Pyx-106 Phase 1 trial search interest

There is not enough data for Pyx-106 Phase 1 trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pyx-106 Phase 1 trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pyx-201 Phase 1 trial to provide analysis

Correlation between past revenue and Pyx-201 Phase 1 trial search interest

There is not enough data for Pyx-201 Phase 1 trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pyx-201 Phase 1 trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pyxis Oncology headquarters to provide analysis

Correlation between past revenue and Pyxis Oncology headquarters search interest

There is not enough data for Pyxis Oncology headquarters to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pyxis Oncology headquarters to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Pyxis Oncology contact information to provide analysis

Correlation between past revenue and Pyxis Oncology contact information search interest

There is not enough data for Pyxis Oncology contact information to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Pyxis Oncology contact information to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PYXS
Earnings date: 2024-03-22 After close
Company name: Pyxis Oncology Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T11:00:00Z

GlobeNewswire
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

2026-05-13T11:30:00Z

GlobeNewswire
Pyxis Oncology to Participate in Upcoming Investor Conferences

2026-05-07T20:05:00Z

GlobeNewswire
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

2026-05-05T13:26:49Z

Analyst Upgrades
Wedbush Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $6

2026-04-17T20:05:00Z

GlobeNewswire
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

2026-03-24T11:06:01Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target

2026-03-23T11:00:00Z

GlobeNewswire
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

2026-02-03T11:45:00Z

GlobeNewswire
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

2026-01-12T15:14:09Z

GlobeNewswire
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

2025-12-19T15:17:53Z

Analyst Upgrades
RBC Capital Maintains Outperform on Pyxis Oncology, Lowers Price Target to $5

2025-12-19T14:07:43Z

Analyst Upgrades
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

2025-12-19T12:47:18Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7

2025-12-18T12:00:00Z

GlobeNewswire
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2025-11-24T14:04:08Z

Analyst Upgrades
Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8

2025-11-04T15:37:04Z

Analyst Upgrades
Guggenheim Maintains Buy on Pyxis Oncology, Raises Price Target to $7